Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response
NCT03524417 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2022-04-29
Summary
No study was conducted to evaluate the rabies neutralizing antibody titers after RIG injection on day 7. The only study that has supported the delay of RIG administration was done in 1996 by our institute, of which RIG was given on day 5 with the original Thai Red Cross intradermal regimen (2-2-2-0-1-1).
Conditions
- Rabies
Interventions
- BIOLOGICAL
-
Equine rabies immunoglobulin injection on day 7
The patients with WHO category III rabies exposure, who have received first dose of rabies vaccination a week before and have not received rabies immunoglobulin were enrolled. Blood for Rabies neutralizing antibody titers (RNab) would be examined on day 0. On the same day, Equine rabies immunoglobulin (ERIG) at the dosage of 40 IU/kg would be injected into and around the wound as much as possible and the rest would be injected intramuscularly at the site distance from rabies vaccine. Then blood for RNab would be serially examined on day 7, 14, 90, 365.
Sponsors & Collaborators
-
Queen Saovabha Memorial Institute
lead OTHER
Principal Investigators
-
Suda Sibunruang, MD · Queen Saovabha Memorial Institute
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-04-30
- Primary Completion
- 2023-12-30
- Completion
- 2023-12-30
Countries
- Thailand
Study Locations
More Related Trials
-
Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects
NCT03264157 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland
NCT04594551 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia
NCT05684185 ·Status: COMPLETED
-
A Comparison of Safety and Immunogenicity of Rabies Pre Exposure Prophylaxis Regimen Between Gvt of India Approved and WHO Approved.
NCT06066294 ·Status: RECRUITING ·Phase: PHASE3
-
Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis
NCT02374814 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG
NCT01137045 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
NCT07120464 ·Status: RECRUITING
-
Rabies Immune Plasma Booster Study
NCT01063140 ·Status: COMPLETED
-
A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children
NCT02991872 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen
NCT07055295 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Prevention of Rabies With Four Doses of Rabies Vaccine
NCT05545371 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children
NCT02339896 ·Status: UNKNOWN
-
Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults
NCT01228383 ·Status: COMPLETED ·Phase: PHASE2
-
Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year
NCT03700242 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Verorab™ in Indian Population
NCT00260351 ·Status: COMPLETED ·Phase: PHASE4
-
Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV
NCT01603875 ·Status: COMPLETED ·Phase: NA
-
Immunity Duration of Rabies Vaccine and Booster Dose Effects at 10 Years Post-primary Vaccination
NCT03774628 ·Status: COMPLETED ·Phase: NA
-
Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
NCT06548139 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen
NCT01622062 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules
NCT01365494 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen
NCT07055893 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
NCT02040090 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects
NCT04019444 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)
NCT05969626 ·Status: UNKNOWN ·Phase: PHASE3
-
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen
NCT01930357 ·Status: COMPLETED ·Phase: PHASE2